Business Context and Reporting Period
Company: Texas Ventures Acquisition III Corp (TVAC)
Reporting Period: Quarter ended March 31, 2025
Status: Pre-IPO Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands. The company was formed to effect a business combination with one or more target businesses. As of the balance sheet date, the company had not yet consummated its Initial Public Offering (IPO), which occurred subsequently on April 24, 2025.
Key Financial Metrics
| Metric | March 31, 2025 | December 31, 2024 |
|---|---|---|
| Total Assets | $1,040,344 | $255,223 |
| Cash and Cash Equivalents | $602,518 | $2,232 |
| Total Liabilities | $1,099,677 | $274,960 |
| Shareholders' Deficit | $(59,333) | $(19,737) |
| Net Loss (3 Months) | $(39,596) | N/A |
| Net Loss Per Share | $(0.01) | N/A |
Debt and Liquidity: The company held a promissory note payable to a related party of $279,200. A related party payable of $601,540 represented advance payments for Private Placement Warrants received prior to the IPO closing. The company reported a working capital deficit of $59,333.
Material Changes and Subsequent Events
The most significant event occurred subsequent to the reporting period (April 24, 2025):
- Initial Public Offering (IPO): The company consummated an IPO of 22,500,000 Units at $10.00 per unit, generating gross proceeds of $225,000,000. This included a partial exercise of the underwriters' over-allotment option for 2,500,000 units.
- Private Placement: Simultaneously, the company sold 7,568,750 Private Placement Warrants for $7,568,750.
- Trust Account: $226,125,000 ($10.05 per unit) was deposited into a Trust Account.
- Debt Repayment: The outstanding promissory note balance of $300,000 was repaid in full upon the IPO closing.
- Share Forfeiture: Due to the partial exercise of the over-allotment option, 166,667 Founder Shares were forfeited and cancelled.
Quarter-over-Quarter Changes (Pre-IPO):
- Cash increased from $2,232 to $602,518, primarily due to proceeds from a related party promissory note ($127,000) and advances for the private placement ($601,540).
- Deferred offering costs increased from $248,425 to $431,902 as the company prepared for the IPO.
- Accrued offering costs increased from $122,760 to $214,937.
Outlook, Risks, and Management Commentary
Outlook: Management intends to use funds held outside the Trust Account to identify and evaluate target businesses. The company has until October 24, 2026 (18 months from IPO) to consummate a business combination, subject to extensions.
Risks and Contingencies:
- Going Concern: The filing notes substantial doubt about the company's ability to continue as a going concern for one year from the issuance date if a business combination is not consummated, though management believes proceeds from the IPO (subsequent event) will satisfy liquidity needs.
- Market Risk: Risks include global economic uncertainty, trade tensions (specifically U.S.-China and Russia-Ukraine conflicts), and potential changes in SEC SPAC regulations adopted in 2024.
- Delisting Risk: If the company fails to complete a business combination within 36 months of the IPO registration effectiveness, Nasdaq may suspend trading and delist the securities.
- Warrant Dilution: Non-managing sponsor investors hold warrants with unique exchange rights that could lead to significant dilution for public shareholders if the market price declines.
Investor Verification Checklist
- IPO Closing Confirmation: Verify the final closing date and total proceeds of the April 24, 2025 IPO, including the exact amount remaining in the Trust Account after transaction costs.
- Trust Account Composition: Confirm the specific investments held within the Trust Account (U.S. government securities vs. money market funds) and the interest rate environment affecting the $10.05 per share redemption value.
- Related Party Transactions: Review the terms of the Administrative Services Agreement ($10,000/month) and the status of the Working Capital Loans available from the Sponsor.
- Warrant Terms: Scrutinize the specific redemption triggers ($18.00 per share) and the unique exchange rights of the NMSI Private Placement Warrants which may impact dilution.
- Extension Provisions: Understand the specific shareholder approval requirements and potential costs associated with extending the combination period beyond the initial 18 months.